Search

Each record is a registered study, a systematic-review registration or a publication. A registered or ongoing study is not a finding, and animal or cell research does not show an effect in people. The same study can appear under more than one subject, so the number of records is not a count of independent studies. You can also search an exact DOI, PubMed ID, NCT or CRD number. How to read these records.

30 study records (showing up to 30 per record type)

• Systematic review registration CRD42023495362 Registered protocol, no results here: Review Ongoing
  Use of cannabidiol for the treatment of oral mucositis: a systematic review
  Condition or outcome area: Oral mucositis are lesions associated to the cytotoxic effects of chemo- and/or radiotherapy (RT). When the oral cavity is affected, mucositis can lead to pain, inability to eat, weight loss, and local infections [1]. In order to give a better quality of life to the affected patients, different treatment options, including cannabidiol have been assessed. Cannabidiol is a component extracted from cannabis sativa, that has effects on central nervous system and has been tested in clinical trials in
  2023-12-30 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023487877 Registered protocol, no results here: Review Ongoing
  Medicinal cannabis to treat anxiety disorders: A Systematic Review
  Condition or outcome area: The condition being studied is anxiety disorder. We will use the DSM-V criteria to define anxiety, which as follows “excessive anxiety and worry (apprehensive expectation) occurring more days than not for at least six months about a number of events or activities, with individuals finding it difficult to control the worry” (2). Anxiety disorders in this review will include conditions such as General Anxiety Disorder, Social Anxiety Disorder, Obsessive-Compulsive Disorder (OCD), Post-Traumatic St
  2023-12-12 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023486185 Registered protocol, no results here: Review Ongoing
  Efficacy and safety of medical cannabis in pain management – an umbrella review
  Condition or outcome area: Efficacy and safety of medical cannabis will be studied in patients of all ages, with acute pain or chronic pain (duration of more than 3 months). All types of pain will be condidered : neuropathic pain, headaches and migraines, cancer pain, primary pain, visceral pain, musculoskeletal pain, traumatic pain (nociceptive / neuropathic / nociplastic).
  2023-12-05 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023485130 Registered protocol, no results here: Review Ongoing
  Efficacy, Tolerability and Safety of Add-on Third‑Generation Antiseizure Medications in Ttreating the Focal‑Onset Seizures Worldwide: A Network Meta‑analysis of Randomized Placebo-Controlled Trials
  Condition or outcome area: Consequently, add-on therapy with newer ASMs is now considered standard care for patients with refractory epilepsy During the last decade, a number of newer ASMs with more desirable safety profile have been introduced into the market in order to offer better seizure control for patients with epilepsy, especially for those with refractory epilepsy. newer ASMs.However, increasing drug options also pose a challenge for doctors in terms of choosing the initial drug, especially because limited data e
  2023-12-03 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023483302 Registered protocol, no results here: Review Ongoing
  Does Cannabidiol (CBD) Supplementation Attenuate Muscle Damage Markers and Soreness after Resistance Exercise in healthy adult? A Meta-Analysis of Randomized Controlled Trials
  Condition or outcome area: This meta- analysis aimed to summarize the evidence regarding the effect of CBD supplementation on plasma muscle damage markers and soreness after resistance exercise.
  2023-11-26 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023482090 Registered protocol, no results here: Review Ongoing
  A Systematic Review and Meta-Analysis of the Neurocognitive Consequences of Cannabis Use in People with HIV
  Condition or outcome area: The overall goal of this systematic review is to evaluate the neurocognitive effects of past/current cannabis use in the management of HIV-associated health complications for adults living with HIV. To accomplish this, this systematic review and meta-analysis aims to pool estimates on individual neuropsychological tests categorized into several cognitive domains (i.e. global fluid cognition, attention/working memory, learning, processing speed, executive function, verbal fluency, and motor abili
  2023-11-22 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023480695 Registered protocol, no results here: Review Ongoing
  Does co-administration of cannabidiol influence the plasma availability of delta-9-tetrahydrocannabinol in humans? A systematic review and meta-analysis.
  Condition or outcome area: Pharmacokinetics (Cmax, AUC0-t, AUC0-inf) of THC plasma concentrations after acute administration of THC-only or THC in combination with CBD in humans.
  2023-11-20 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023479815 Registered protocol, no results here: Review Ongoing
  Prospective analysis of cannabidiol's effectiveness in post-exercise recovery: an integrated review and research agenda
  Condition or outcome area: Recovery between physical efforts is essential to achieving optimal performance in sports. Depending on the exercise intensity, fatigue can manifest in different ways (e.g., myositis, energy depletion), thus triggering inflammatory responses and compromising the effectiveness and efficiency of recovery processes. Dietary supplements have been proposed to achieve recovery and subsequent performance optimization. Recently, supplementation with organic products has gained interest in the area of sp
  2023-11-17 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023467536 Registered protocol, no results here: Review Ongoing
  Cannabinoids for the treatment of mental and substance use disorders, and the symptoms of mental and substance use disorders: An updated systematic review and meta-analysis
  Condition or outcome area: The use of cannabis as a treatment option has remained of interest to the general population as legislation for medicinal cannabis continues to expand globally. For example, from October 31 2016 the Commonwealth Department of Health in Australia has overseen a regulated system of cannabinoid products for medicinal use. Black et al. (2019) systematically reviewed the use of cannabinoids for mental disorders and highlighted a lack of evidence for improvements across almost all included mental diso
  2023-11-14 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023462484 Registered protocol, no results here: Review Ongoing
  The Effects of Cannabis on Sleep Architecture: a Systematic Review
  Condition or outcome area: Sleep
  2023-09-21 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023457536 Registered protocol, no results here: Review Ongoing
  Neuroprotective effects of cannabidiol in neurodegeneration and brain aging models: A systematic review of preclinical studies in rodents.
  2023-10-17 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023457464 Registered protocol, no results here: Review Ongoing
  Artisanal preparations of medicinal cannabis: composition and reported effectiveness in epilepsy.
  Condition or outcome area: Epilepsy is defined as a disease of the brain defined by any of the following conditions -At least two unprovoked (or reflex) seizures occurring >24 h apart -One unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years -Diagnosis of an epilepsy syndrome
  2023-09-04 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023449955 Registered protocol, no results here: Review Ongoing
  The use of cannabidiol (CBD) in adult patients with drug resistant epilepsy (DRE): A Systematic Review
  Condition or outcome area: Drug resistant epilepsy (DRE). Cannabidiol (CBD).
  2023-08-10 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023447217 Registered protocol, no results here: Review Ongoing
  Cannabidiol (CBD) for the management of substance use disorders and its relevance for addiction research: an umbrella review
  Condition or outcome area: The condition being studied is substance use disorders (SUD), including all substances, symptoms of their use and reduction or cessation. Substance use disorders (SUD) are characterized by compulsive and abusive behaviors, seeking drugs, independently of dangerous consequences. According to the World Health Organization (WHO), about 35 million people are affected by drug use disorders (WHO, 2023) with the most common disorders being cannabis dependence (22.1 million cases) and opioid dependence
  2023-07-31 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023447171 Registered protocol, no results here: Review Ongoing
  Systematic review on the effectiveness of medical cannabis for the treatment of chronic pain
  Condition or outcome area: Chronic pain is defined as pain that persists for more than three months despite being treated. It can be of different types, including peripheral or central neuropathic pain, nociceptive pain due to tissue injuries, musculoskeletal pain affecting joints, back or neck, and inflammatory pain associated with infections or autoimmune conditions, like rheumatoid arthritis. Other conditions such as fibromyalgia and chronic pain of unknown aetiology, may also contribute to chronic pain. Unfortunately,
  2023-09-01 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023444136 Registered protocol, no results here: Review Completed not published
  Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: a network meta-analysis
  Condition or outcome area: Dravet syndrome (DS) is a rare and severe developmental and epileptic encephalopathy. It is characterised by frequent, convulsive seizures arising in the first year of life, followed by developmental delay and cognitive impairment, which impair patient and carer quality of life. Sufferers are at a high risk of premature death, primarily due to the risks of status epilepticus (SE) and sudden unexplained death in epilepsy (SUDEP); 15-20% of children with DS die before reaching adulthood. In DS, hi
  2023-07-24 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023443917 Registered protocol, no results here: Review Ongoing
  Cannabidiol and Hepatotoxicity in Adult Populations: A Systematic Review and Meta-analysis of Randomized Controlled Trials
  Condition or outcome area: Hepatoxicity risk related to cannabidiol.
  2023-07-23 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023441238 Registered protocol, no results here: Review Ongoing
  Cannabinoid interventions for childhood epilepsy seizures: Dravet syndrome, Lennox-Gastaut syndrome, West syndrome, and tuberous sclerosis
  Condition or outcome area: Epilepsy in people up to 12 years old.
  2023-07-11 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023439368 Registered protocol, no results here: Review Ongoing
  Cannabinoids and Pain Relief - an overview of systematic reviews
  Condition or outcome area: Pain relief in various conditions or domains, including but not limited to: Neuropathic pain Chronic non-cancer pain Cancer-related pain Pain associated with specific conditions (e.g., rheumatic diseases, fibromyalgia, osteoarthritis)
  2023-07-07 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023432881 Registered protocol, no results here: Review Ongoing
  Cannabidiol in postoperative adjuvant analgesia for orthopedic surgery: systematic review
  Condition or outcome area: Efficacy of cannabidiol use for postoperative analgesia in orthopedic surgeries.
  2023-07-14 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023430465 Registered protocol, no results here: Review Ongoing
  Effectiveness of oromucosal medicinal cannabis to reduce chronic musculoskeletal pain in adult patients. A Systematic Review with Meta-analysis.A systematic review with meta-analysis of the effectiveness of medical cannabis administered through the oromucosal route for the control of chronic non-cancer pain in adult patients will be carried out.
  Condition or outcome area: According to the WHO, chronic pain is defined as an unpleasant sensory and emotional experience associated with tissue damage. For the population of Colombia, 76% of people have reported having presented some kind of pain, of this population 47% have perceived pain for more than three months; and in 64.5% it was due to musculoskeletal pathology pain; and 32% of people have had work incapacity because of it. Currently, for the treatment of chronic pain, different opioid and non-opioid analgesics
  2023-06-09 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023426534 Registered protocol, no results here: Review Ongoing
  Efficacy and Safety of Cannabidiol as an Adjuvant Therapy for Refractory Epilepsy: A Systematic Review and Meta-Analysis
  Condition or outcome area: Epilepsy is one of the most common chronic diseases of the nervous system, characterized by frequent spontaneous and recurrent unprovoked seizures, affecting about 70 million people worldwide. Its annual incidence is 80 cases per 100, 000 people and the prevalence is 4 to 10 cases per 1000 people. Although the majority of patients with epilepsy respond to medication or improve with age, one-third of patients with epilepsy continue to have seizures after medication, surgery, or dietary interventi
  2023-05-25 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023408867 Registered protocol, no results here: Review Ongoing
  Effectiveness of oromucosal medicinal cannabis, compared with opioids, to reduce chronic musculoskeletal pain in adult patients. A Systematic Review with Meta-analysis.
  Condition or outcome area: Chronic pain is defined as an unpleasant sensory and emotional experience associated with tissue damage, which leads to people being unable to work, reducing the quality of life and affecting the economy of countries. For the treatment of chronic pain, different opioid and non-opioid analgesics are used, on the other hand, medical cannabis has been used since ancient times by different cultures, in pain management.
  2023-03-27 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023407111 Registered protocol, no results here: Review Ongoing
  Neural activation and symptomatological impacts of cannabidiol (CBD) in the treatment of schizophrenia: A systematic review and meta-analysis
  Condition or outcome area: We are studying schizophrenia, which is mental health condition characterized by positive symptoms (delusions and hallucinations) and negative symptoms (anhedonia and avolition).
  2023-03-21 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023405747 Registered protocol, no results here: Review Ongoing
  The effectiveness of cannabidiol in the treatment of mental disorders: a systematic review of double-blind randomized controlled trials
  Condition or outcome area: This review is goint to evaluate the use of Cannabidiol on the treatment of mental disorders
  2023-04-17 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023402998 Registered protocol, no results here: Review Ongoing
  Monotherapy for epilepsy complicated by drop attacks: A systematic review and meta-analysis
  Condition or outcome area: PubMed, MedlinePlus, Cochrane Database of Systematic Reviews, Cochrane Evidence, Europe PMC, and EBSCOhost. ClinicalTrials.gov will also be searched for any currently conducted or finished but not yet published studies that corresponded to the research question topic. GreyNet.org and greylit.org will also be searched to identify possible grey literature sources that meet inclusion criteria. Articles will not be limited by date, subject, or type in order to increase search query. A search of Goog
  2023-03-08 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023401446 Registered protocol, no results here: Review Ongoing
  Cannabidiol in the Context of Opioid Use Disorder: A Systematic Review
  Condition or outcome area: Opioid Use Disorder
  2023-03-04 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023401401 Registered protocol, no results here: Review Ongoing
  Cardiovascular risk associated with the use of cannabis and cannabis-based products: a systematic review and meta-analysis of recent evidence relating to real-life data
  Condition or outcome area: The consequences of cannabis or cannabis-based products on the cardiovascular health of users are defined as any health disorder affecting the vessels and/or organs likely to be the site of a cardiovascular complication including the heart and brain.
  2023-03-07 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42023381113 Registered protocol, no results here: Review Ongoing
  Efficacy and safety of cannabidiol for the treatment of canine osteoarthritis: a systematic review and meta-analysis of animal intervention studies
  2023-01-17 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record
• Systematic review registration CRD42022380182 Registered protocol, no results here: Review Ongoing
  A Systematic Review of Cannabidiol (CBD): Inhalation Toxicity and Documented Health Effects of Vape Exposures
  Condition or outcome area: Inhalation toxicity
  2022-12-10 · Subject: Cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; Cannabidiol [USAN] · open the ingredient record